KR101670904B1 - Imidazole derivative and organic electroluminescent device including the same - Google Patents

Imidazole derivative and organic electroluminescent device including the same Download PDF

Info

Publication number
KR101670904B1
KR101670904B1 KR1020140150036A KR20140150036A KR101670904B1 KR 101670904 B1 KR101670904 B1 KR 101670904B1 KR 1020140150036 A KR1020140150036 A KR 1020140150036A KR 20140150036 A KR20140150036 A KR 20140150036A KR 101670904 B1 KR101670904 B1 KR 101670904B1
Authority
KR
South Korea
Prior art keywords
mmol
compound
layer
synthesis
imidazole derivative
Prior art date
Application number
KR1020140150036A
Other languages
Korean (ko)
Other versions
KR20160050891A (en
Inventor
고병수
오유진
Original Assignee
(주)더블유에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)더블유에스 filed Critical (주)더블유에스
Priority to KR1020140150036A priority Critical patent/KR101670904B1/en
Publication of KR20160050891A publication Critical patent/KR20160050891A/en
Application granted granted Critical
Publication of KR101670904B1 publication Critical patent/KR101670904B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

하기 화학식 1로 표시되는 이미다졸 유도체가 제공된다.
[화학식 1]

Figure 112014105058503-pat00118

[상기 화학식 1에서 각 치환기들의 정의는 발명의 상세한 설명에서 정의한 바와 같다.]There is provided an imidazole derivative represented by the following formula (1).
[Chemical Formula 1]
Figure 112014105058503-pat00118

[Wherein the definition of each substituent in Formula 1 is as defined in the description of the invention]

Description

이미다졸 유도체 및 이를 포함한 유기 전계발광 소자{Imidazole derivative and organic electroluminescent device including the same}The present invention relates to an imidazole derivative and an organic electroluminescent device including the same,

본 발명은 이미다졸 유도체 및 이를 포함한 유기 전계발광 소자에 관한 것으로, 특히 발광 효율이 높은 유기 전계발광 소자 및 이를 위한 신규한 이미다졸 유도체에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an imidazole derivative and an organic electroluminescent device including the same. More particularly, the present invention relates to an organic electroluminescent device having high luminous efficiency and a novel imidazole derivative for the same.

유기전계발광 소자(Organic electroluminescent device)는 형광성 유기 화합물에 전류가 흐르면 스스로 빛을 내는 자체 발광형 유기물질을 말하며, 유기발광 다이오드(Organic Light emitting Diodes, 이하 'OLED')로도 지칭된다.An organic electroluminescent device refers to a self-emitting organic material that emits light when a current flows through a fluorescent organic compound, and is also referred to as an organic light emitting diode (OLED).

OLED는 별도의 광원이 필요 없어서 훨씬 얇게 만들 수 있으며 플라스틱 같은 휠 수 있는(flexible) 투명 기판 위에도 소자를 형성 할 수 있을 뿐 아니라, 플라즈마 디스플레이 패널(Plasma Display Panel)이나 무기 전계 발광(EL) 디스플레이에 비해 10V 이하의 낮은 전압에서 구동이 가능하고, 소비 전력이 매우 적으면서도 자연색을 완벽하게 표현하며, 모든 방향에서 빛이 방출되기 때문에 시야각 또한 넓으며 화소의 응답 속도 또한 마이크로 초이하로 매우 빠르기 때문에 고화질의 동영상을 표현할 수 있다. 또한 다른 디스플레이에 비교하여 제조 공정이 간단하여 생산 비용이 낮다는 장점을 가지고 있어서 가장 유망한 차세대 평판 디스플레이로서 각광받고 있다.OLEDs can be made much thinner because they do not require a separate light source and can be formed on a flexible transparent substrate such as a plastic as well as on a plasma display panel or an inorganic electroluminescence It can be driven at a voltage as low as 10V or less, completely expresses natural colors with very low power consumption, emits light in all directions, has wide viewing angle, and the response speed of pixels is also very fast, Can be displayed. In addition, it has a merit that manufacturing process is simple compared with other displays and its production cost is low, and thus it is attracting attention as the most promising next generation flat panel display.

이러한 OLED는 1963년 Pope 등에 의하여 안트라센(Anthracene) 방향족 탄화수소의 단결정을 이용한 캐리어 주입형 전계발광(Electroluminescence; EL)의 연구가 최초로 시도되었고, 이러한 연구로부터 유기물에서의 전하주입, 재결합, 여기자 생성, 발광 등의 기초적 메커니즘과 전기발광 특성 등에 대한 많은 이해와 연구가 시작되었다.This OLED was first attempted in 1963 by Pope et al. To study the carrier injection type electroluminescence (EL) using an anthracene aromatic hydrocarbon single crystal. From these studies, it was found that charge injection, recombination, exciton generation, And the basic mechanism of electroluminescence and electroluminescence characteristics.

또한, 1987년 Tang과 Van Slyke가 유기전계발광소자의 다층 박막 구조를 이용하여 고효율의 특성을 보고한 이후 [Tang, C. W., Van Slyke, S. A. Appl. Phys. Lett. 51, 913 (1987)], OLED는 차세대 디스플레이로서의 우수한 특성 뿐만 아니라 LCD 배면광 및 조명 등에 사용가능한 높은 잠재력을 가지고 있어 각광을 받으며 많은 연구가 진행되고 있다[Kido, J., Kimura, M., and Nagai, K., Science 267, 1332 (1995)]. 특히 발광 효율을 높이기 위해 소자의 구조 변화 및 물질 개발 등 다양한 접근이 이루어지고 있다[Sun, S., Forrest, S. R., Appl. Phys. Lett. 91, 263503 (2007)/Ken-Tsung Wong, Org. Lett., 7, 2005, 5361-5364]. In addition, after Tang and Van Slyke in 1987 reported the characteristics of high efficiency using a multilayer thin film structure of organic electroluminescent devices [Tang, C. W., Van Slyke, S. A. Appl. Phys. Lett. 51, 913 (1987)], OLEDs have a high potential for use in LCD backlighting and illumination as well as excellent characteristics as a next generation display, and many studies have been conducted under the spotlight [Kido, J., Kimura, M., and Nagai, K., Science 267,1332 (1995)]. Especially, in order to increase the luminous efficiency, various approaches such as structural change and material development have been performed [Sun, S., Forrest, S. R., Appl. Phys. Lett. 91, 263503 (2007) / Ken-Tsung Wong, Org. Lett., 7, 2005, 5361-5364].

OLED 디스플레이의 기본적 구조는 일반적으로 양극(Anode), 정공주입층(Hole Injection Layer, HIL), 정공수송층(Hole Transporting Layer, HTL), 발광층 (Emission Layer, EML), 전자수송층(Electron Transporting Layer, ETL), 그리고 음극(Cathode)의 다층 구조로 구성되며, 전자 유기 다층막이 양 전극 사이에 형성된 샌드위치 구조로 되어 있다. 이러한 구조에서 양 전극 사이에 전압을 걸어주게 되면 양극에서는 정공이, 음극에서는 전자가 유기물층에 주입되게 되고, 주입된 정공과 전자가 만났을 때 엑시톤(exction)이 형성되며, 이 엑시튼의 전기에너지가 빛에너지로 전환되는 과정에서 발광층의 에너지 밴드 갭에 해당하는 색상의 빛을 방출한다. 이때. 발광층을 구성하고 있는 유기 물질이 어떤 것이냐에 따라 빛의 색깔이 달라지며, 발광 물질만 사용하는 경우 분자 간 상호작용에 색 순도와 발광 효율일 떨어지게 되는 문제가 있어 호스트(host)/도판트(dopant) 구조를 많이 사용한다. The basic structure of an OLED display generally includes an anode, a hole injection layer (HIL), a hole transporting layer (HTL), an emission layer (EML), an electron transporting layer (ETL) ), And a cathode (cathode), and the electron-emitting organic multi-layer film has a sandwich structure formed between both electrodes. When a voltage is applied between both electrodes in this structure, holes are injected into the anode and electrons from the cathode are injected into the organic layer. When excited holes and electrons meet, an excition is formed. And emits light of a color corresponding to the energy band gap of the light emitting layer in the course of conversion into light energy. At this time. The color of the light varies depending on the organic material constituting the light emitting layer. In the case of using only the light emitting material, there is a problem that the color purity and the light emitting efficiency are less than the intermolecular interaction. Therefore, the host / dopant ) Structure.

발광물질의 삼원색 중 청색물질과 관련해서는 4,4'-bis(2,2-diphenylvinyl)-1,1'-biphenyl (DPVBi), TBSA 계열의 물질이 개발된 바 있으며, 특히 idemitsu-kosan의 디스트릴(distyryl) 화합물이 좋은 성능을 보이는 것으로 알려져 있다.As for the blue color of the three primary colors of the luminescent material, 4,4'-bis (2,2-diphenylvinyl) -1,1'-biphenyl (DPVBi) and TBSA series materials have been developed. Particularly, in the case of idemitsu- Distyryl compounds are known to exhibit good performance.

Figure 112014105058503-pat00001
Figure 112014105058503-pat00002
Figure 112014105058503-pat00001
Figure 112014105058503-pat00002

그러나 청색 발광 재료의 경우 색순도 및 효율, 장기적 열적안정성 등의 문제로 충분한 수명을 확보하지 못하여 실제 상용 제품에 사용되는 재료들은 극히 제한적이어서 재료의 개발이 계속 요구되고 있다.However, the blue light emitting material can not secure a sufficient lifetime due to problems such as color purity and efficiency, long-term thermal stability, and the materials used in practical commercial products are extremely limited, so development of materials is continuously required.

대한민국 공개특허 제2014-0009095호Korea Patent Publication No. 2014-0009095

본 발명의 과제는 종래의 재료보다 발광효율이 우수하고 내구성이 뛰어난 신규한 이미다졸 유도체를 제공하는 것이며, 또한 상기 이미다졸 유도체가 유기막에 포함되어 낮은 구동전압으로 높은 발광 효율 및 긴 수명의 유기 전계발광 소자를 제공하는 것이다.The object of the present invention is to provide a novel imidazole derivative excellent in luminous efficiency and durability as compared with conventional materials, and that the imidazole derivative is contained in an organic film to provide a high luminous efficiency and a long lifetime And to provide an organic electroluminescent device.

본 발명의 일 측면에 의하면, 하기 화학식 1로 표시되는 이미다졸 유도체가 제공된다.According to one aspect of the present invention, an imidazole derivative represented by the following formula (1) is provided.

[화학식 1][Chemical Formula 1]

Figure 112014105058503-pat00003
Figure 112014105058503-pat00003

[상기 화학식 1에서 A는 치환 또는 비치환된 C6~C30의 아릴이거나, 치환 또는 비치환된 C5~C30의 헤테로아릴이거나, 치환 또는 비치환된 C1~C30의 알킬이거나, 치환 또는 비치환된 C3~C30의 시클로알킬이거나, 치환 또는 비치환된 C1~C10의 알콕시이고,[In Formula 1 A is aryl substituted or unsubstituted C 6 ~ C 30, substituted or non-substituted or heteroaryl-substituted C 5 ~ C 30, or a substituted or unsubstituted alkyl of the unsubstituted C 1 ~ C 30, A substituted or unsubstituted C 3 to C 30 cycloalkyl, a substituted or unsubstituted C 1 to C 10 alkoxy,

p는 1 또는 2이고,p is 1 or 2,

L은 단일결합이고,L is a single bond,

q는 0 또는 1이다.]
q is 0 or 1.]

본 발명의 다른 측면에 의하면, 상기 이미다졸 유도체를 포함하는 유기 전계발광 소자가 제공된다.According to another aspect of the present invention, there is provided an organic electroluminescent device comprising the imidazole derivative.

본 발명의 또 다른 측면에 의하면, 제1 전극, 제2 전극, 및 상기 전극들 사이에 배치된 1층 이상의 유기막을 포함하되, 상기 유기막은 상기 이미다졸 유도체를 포함하는 유기 전계발광 소자가 제공된다.According to another aspect of the present invention, there is provided an organic electroluminescent device comprising a first electrode, a second electrode, and at least one organic film disposed between the electrodes, wherein the organic film comprises the imidazole derivative .

본 발명의 또 다른 측면에 의하면, 상기 이미다졸 유도체가 상기 유기막을 구성하는 전자저지층, 전자수송층, 전자주입층, 전자수송 기능과 전자주입 기능을 동시에 갖는 기능층 및 발광층으로 이루어진 군 중에서의 선택된 어느 1층에 포함되는 것을 특징으로 하는 유기 전계발광 소자가 제공된다.According to still another aspect of the present invention, the imidazole derivative is selected from the group consisting of an electron blocking layer, an electron transporting layer, an electron injecting layer, a functional layer having both an electron transporting function and an electron injecting function, The organic electroluminescent device is characterized in that it is contained in any one layer.

본 발명의 일 실시예에 따른 이미다졸 유도체는 유기 전계발광 소자의 유기막에 포함되어 소자의 구동전압을 낮추고 발광 효율이 개선되며 수명을 연장시킬 수 있다. The imidazole derivative according to an embodiment of the present invention may be included in the organic layer of the organic electroluminescent device to lower the driving voltage of the device, improve the luminous efficiency, and prolong the lifetime.

도 1은 본 발명의 일 실시예에 따른 유기 전계발광 소자의 개략적인 단면도이다.
도 2는 비교시험예 및 시험예 1 및 2에서 제조된 유기 전계발광 소자의 EL peak를 나타내는 그래프이다.
1 is a schematic cross-sectional view of an organic electroluminescent device according to an embodiment of the present invention.
2 is a graph showing EL peaks of the organic electroluminescent devices manufactured in the comparative test examples and Test Examples 1 and 2. Fig.

본 명세서에서 용어 "아릴"은 다른 의미로 명시되지 않는 한, 단일 고리이거나 융합 또는 공유 결합된 다중 고리(1개 내지 3개의 고리)일 수 있는 다중불포화 방향족 탄화수소 치환기를 의미한다.As used herein, the term "aryl " means a polyunsaturated aromatic hydrocarbon substituent, which may be a single ring or a multiple ring (1 to 3 rings) fused or covalently bonded unless otherwise specified.

"헤테로아릴"이란 용어는 (다중 고리의 경우 각각의 별도의 고리에서) N, O 및 S로부터 선택되는 1 내지 4개의 이종원자를 포함하는 아릴 기(또는 고리)를 의미하고, 질소 및 황 원자는 경우에 따라 산화되고, 질소 원자(들)은 경우에 따라 4차화된다. 헤테로아릴 기는 탄소 또는 이종원자를 통해 분자의 나머지에 결합될 수 있다.The term "heteroaryl" means an aryl group (or a ring) comprising one to four heteroatoms selected from N, O and S (in each case on a separate ring in the case of multiple rings) Optionally oxidized, and the nitrogen atom (s) are quaternized, as the case may be. Heteroaryl groups can be attached to the remainder of the molecule through carbon or heteroatoms.

상기 아릴은 각 고리에 적절하게는 4 내지 7개, 바람직하게는 5 또는 6개의 고리원자를 포함하는 단일 또는 융합고리계를 포함한다. 또한, 하나 이상의 아릴이 화학결합을 통하여 결합되어 있는 구조도 포함한다. 상기 아릴의 구체적인 예로 페닐, 나프틸, 비페닐, 안트릴, 인데닐, 플루오레닐, 페난트릴, 트라이페닐레닐, 피렌일, 페릴렌일, 크라이세닐, 나프타세닐, 파이렌일, 플루오란텐일 등을 포함하지만, 이에 한정되지 않는다.The aryl includes a single or fused ring system, suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring. Also included are structures in which one or more aryls are attached through a chemical bond. Specific examples of the aryl include phenyl, naphthyl, biphenyl, anthryl, indenyl, fluorenyl, phenanthryl, triphenylenyl, pyrenyl, perylenyl, But are not limited thereto.

상기 헤테로아릴은 5 내지 6원 단환 헤테로아릴, 및 하나 이상의 벤젠 환과 융합된 다환식 헤테로아릴을 포함하며, 부분적으로 포화될 수도 있다. 또한, 하나 이상의 헤테로아릴이 화학결합을 통하여 결합되어 있는 구조도 포함된다. 상기 헤테로아릴기는 고리 내 헤테로원자가 산화되거나 사원화되어, 예를 들어 N-옥사이드 또는 4차 염을 형성하는 2가 아릴 그룹을 포함한다.The heteroaryl includes 5- to 6-membered monocyclic heteroaryl and polycyclic heteroaryl fused with one or more benzene rings, and may be partially saturated. Also included are structures in which one or more heteroaryls are attached via a chemical bond. The heteroaryl groups include divalent aryl groups in which the heteroatoms in the ring are oxidized or trisubstituted to form, for example, an N-oxide or a quaternary salt.

상기 헤테로아릴의 구체적인 예로 퓨릴, 티오펜일, 피롤릴, 이미다졸릴, 피라졸릴, 티아졸릴, 티아디아졸릴, 이소티아졸릴, 이속사졸릴, 옥사졸릴, 옥사디아졸릴, 트리아진일, 테트라진일, 트리아졸릴, 테트라졸릴, 퓨라잔일, 피리딜, 피라진일, 피리미딘일, 피리다진일 등의 단환 헤테로아릴, 벤조퓨란일, 벤조티오펜일, 이소벤조퓨란일, 벤조이미다졸릴, 벤조티아졸릴, 벤조이소티아졸릴, 벤조이속사졸릴, 벤조옥사졸릴, 이소인돌릴, 인돌릴, 인다졸릴, 벤조티아디아졸릴, 퀴놀릴, 이소퀴놀릴, 신놀리닐, 퀴나졸리닐, 퀴녹살리닐, 카바졸릴, 페난트리딘일, 벤조디옥솔릴 등의 다환식 헤테로아릴 및 이들의 상응하는 N-옥사이드(예를 들어, 피리딜 N-옥사이드, 퀴놀릴 N-옥사이드), 이들의 4차 염 등을 포함하지만, 이에 한정되지 않는다.Specific examples of the heteroaryl include furyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazinyl, tetrazinyl, Monocyclic heteroaryl such as pyridyl, pyridyl, pyrazinyl, pyridazinyl and the like, benzofuranyl, benzothiophenyl, isobenzofuranyl, benzoimidazolyl, benzothiazolyl , Benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, isoindolyl, indolyl, indazolyl, benzothiadiazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, (Such as pyridyl N-oxide, quinolyl N-oxide), quaternary salts thereof, and the like, but are not limited thereto. But is not limited thereto.

본 명세서에 기재된 "치환 또는 비치환된"이라는 표현에서 "치환"은 탄화수소 내의 수소 원자 하나 이상이 각각, 서로 독립적으로, 동일하거나 상이한 치환기로 대체되는 것을 의미한다. 유용한 치환기는 다음을 포함하지만 이에 제한되지 않는다."Substituted" in the expression " substituted or unsubstituted ", as used herein, means that at least one hydrogen atom in the hydrocarbon is each independently replaced with the same or different substituents. Useful substituents include, but are not limited to:

이러한 치환기는, -F; -Cl; -Br; -CN; -NO2; -OH; -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C1~C20 알킬기; -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C1~C20 알콕시기; C1~C20 알킬기, C1~C20 알콕시기, -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C6~C30 아릴기; C1~C20 알킬기, C1~C20 알콕시기, -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C6~C30 헤테로아릴기; C1~C20 알킬기, C1~C20 알콕시기, -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C5~C20 사이클로알킬기; C1~C20 알킬기, C1~C20 알콕시기, -F, -Cl, -Br, -CN, -NO2 또는 -OH로 치환되거나 비치환된 C5~C30 헤테로사이클로알킬기; 및 -N(G1)(G2)으로 표시되는 기로 이루어진 군으로부터 선택된 하나 이상일 수 있다. 이때, 상기 G1 및 G2는 서로 독립적으로 각각 수소; C1~C10 알킬기; 또는 C1~C10 알킬기로 치환되거나 비치환된 C6~C30 아릴기일 수 있다.
Such substituents include, but are not limited to, -F; -Cl; -Br; -CN; -NO 2 ; -OH; A C 1 -C 20 alkyl group which is unsubstituted or substituted by -F, -Cl, -Br, -CN, -NO 2 or -OH; A C 1 -C 20 alkoxy group unsubstituted or substituted by -F, -Cl, -Br, -CN, -NO 2 or -OH; C 1 ~ C 20 alkyl group, C 1 ~ C 20 alkoxy group, -F, -Cl, -Br, -CN , -NO 2, or substituted by -OH or unsubstituted C 6 ~ C 30 aryl group; C 1 ~ C 20 alkyl group, C 1 ~ C 20 alkoxy group, -F, -Cl, -Br, -CN , -NO 2 or -OH-substituted or unsubstituted C 6 ~ C 30 heteroaryl group, a; C 1 ~ C 20 alkyl group, C 1 ~ C 20 alkoxy group, -F, -Cl, -Br, -CN , -NO 2 , or substituted by -OH or unsubstituted C 5 ~ C 20 cycloalkyl group; C 1 ~ C 20 alkyl group, C 1 ~ C 20 alkoxy group, -F, -Cl, -Br, -CN , -NO 2 , or substituted or unsubstituted by -OH unsubstituted C 5 ~ C 30 heterocycloalkyl group; And a group represented by -N (G 1 ) (G 2 ). Wherein G 1 and G 2 are each independently selected from the group consisting of hydrogen; A C 1 -C 10 alkyl group; Or a C 6 -C 30 aryl group substituted or unsubstituted with a C 1 -C 10 alkyl group.

이하, 본 발명에 대해 상세히 설명하고자 한다.Hereinafter, the present invention will be described in detail.

본 발명의 일 실시예에 따른 이미다졸 유도체는 하기 화학식 1로 표시될 수 있다.An imidazole derivative according to an embodiment of the present invention may be represented by the following formula (1).

[화학식 1][Chemical Formula 1]

Figure 112014105058503-pat00004
Figure 112014105058503-pat00004

상기 화학식 1에서 A는 치환 또는 비치환된 C6~C30의 아릴이거나, 치환 또는 비치환된 C5~C30의 헤테로아릴이거나, 치환 또는 비치환된 C1~C30의 알킬이거나, 치환 또는 비치환된 C3~C30의 시클로알킬이거나, 치환 또는 비치환된 C1~C10의 알콕시이고,Wherein A is substituted or unsubstituted C 6 -C 30 aryl, substituted or unsubstituted C 5 -C 30 heteroaryl, substituted or unsubstituted C 1 -C 30 alkyl, or substituted Or unsubstituted C 3 -C 30 cycloalkyl, substituted or unsubstituted C 1 -C 10 alkoxy,

p는 1 또는 2이고,p is 1 or 2,

L은 단일결합이고,L is a single bond,

q는 0 또는 1이다.q is 0 or 1;

상기 화학식 1로 표시되는 화합물은 구체적으로 하기 화학식 2의 구조들 중에서 선택될 수 있다.The compound represented by Formula 1 may be selected from among the structures represented by Formula 2 below.

[화학식 2] (2)

Figure 112014105058503-pat00005
Figure 112014105058503-pat00006
Figure 112014105058503-pat00005
Figure 112014105058503-pat00006

Figure 112014105058503-pat00007
Figure 112014105058503-pat00008
Figure 112014105058503-pat00007
Figure 112014105058503-pat00008

상기 화학식 1 또는 화학식 2에 있어서, 상기 A는 구체적으로 하기 화학식 3에 나열된 구조들 중에서 선택될 수있다.
In formula (1) or (2), A may be selected from among the structures listed in formula (3).

[화학식 3](3)

Figure 112014105058503-pat00009
Figure 112014105058503-pat00010
Figure 112014105058503-pat00011
Figure 112014105058503-pat00012
Figure 112014105058503-pat00009
Figure 112014105058503-pat00010
Figure 112014105058503-pat00011
Figure 112014105058503-pat00012

Figure 112014105058503-pat00013
Figure 112014105058503-pat00014
Figure 112014105058503-pat00015
Figure 112014105058503-pat00016
Figure 112014105058503-pat00013
Figure 112014105058503-pat00014
Figure 112014105058503-pat00015
Figure 112014105058503-pat00016

Figure 112014105058503-pat00017
Figure 112014105058503-pat00018
Figure 112014105058503-pat00019
Figure 112014105058503-pat00020
Figure 112014105058503-pat00017
Figure 112014105058503-pat00018
Figure 112014105058503-pat00019
Figure 112014105058503-pat00020

Figure 112014105058503-pat00021
Figure 112014105058503-pat00022

Figure 112014105058503-pat00021
Figure 112014105058503-pat00022

본 발명의 상기 화학식 1로 표시되는 화합물의 구체적인 예로서, 하기 화학식 4의 화합물을 들 수 있다. 그러나 본 발명의 화학식 1로 표시되는 화합물이 이들 화합물들로 한정되지 않는다.
Specific examples of the compound represented by the formula (1) of the present invention include a compound represented by the following formula (4). However, the compounds represented by Formula 1 of the present invention are not limited to these compounds.

[화학식 4][Chemical Formula 4]

Figure 112014105058503-pat00023
Figure 112014105058503-pat00023

Figure 112014105058503-pat00024
Figure 112014105058503-pat00024

Figure 112014105058503-pat00025
Figure 112014105058503-pat00025

Figure 112014105058503-pat00026
Figure 112014105058503-pat00026

Figure 112014105058503-pat00027
Figure 112014105058503-pat00027

Figure 112014105058503-pat00028
Figure 112014105058503-pat00028

Figure 112014105058503-pat00029
Figure 112014105058503-pat00029

Figure 112014105058503-pat00030
Figure 112014105058503-pat00030

Figure 112014105058503-pat00031
Figure 112014105058503-pat00031

Figure 112014105058503-pat00032
Figure 112014105058503-pat00032

Figure 112014105058503-pat00033
Figure 112014105058503-pat00033

Figure 112014105058503-pat00034
Figure 112014105058503-pat00034

Figure 112014105058503-pat00035
Figure 112014105058503-pat00035

Figure 112014105058503-pat00036
Figure 112014105058503-pat00036

Figure 112014105058503-pat00037
Figure 112014105058503-pat00037

Figure 112014105058503-pat00038

Figure 112014105058503-pat00038

상기 화학식 1로 표시되는 이미다졸 유도체는 공지의 유기 합성방법을 이용하여 합성가능하다. 상기 이미다졸 유도체의 합성방법은 후술하는 실시예를 참조하여 당업자에게 용이하게 인식될 수 있다.The imidazole derivative represented by the above formula (1) can be synthesized using a known organic synthesis method. The method for synthesizing the imidazole derivative can be easily recognized by those skilled in the art with reference to the following examples.

또한 본 발명에 따르면, 상기 화학식 1로 표시되는 이미다졸 유도체를 포함하는 유기 전계발광 소자가 제공된다. Also, according to the present invention, there is provided an organic electroluminescent device comprising an imidazole derivative represented by the above formula (1).

상기 화학식 1의 이미다졸 유도체는 발광층 재료로 유용하며, 이밖에 여러층의 유기 전계발광 소자의 재료로서 사용될 수 있다.The imidazole derivative of Formula 1 is useful as a light emitting layer material, and can be used as a material for various layers of organic electroluminescent devices.

또한 본 발명에 따른 유기 전계발광 소자는 제1 전극, 제2 전극 및 이들 전극 사이에 배치된 1층 이상의 유기막을 포함한다. 상기 유기막은 상기 화학식 1로 표시되는 이미다졸 유도체를 하나 이상 포함한다.The organic electroluminescent device according to the present invention includes a first electrode, a second electrode, and at least one organic film disposed between the electrodes. The organic film contains at least one imidazole derivative represented by the above formula (1).

상기 유기막은 정공주입층, 정공수송층, 정공주입 기능과 정공수송 기능을 동시에 갖는 기능층, 버퍼층, 전자저지층, 발광층, 정공저지층, 전자수송층, 전자주입층, 및 전자수송 기능과 전자주입 기능을 동시에 갖는 기능층으로 이루어진 군 중에서 선택되는 1층 이상을 포함할 수 있다.The organic layer includes a hole injecting layer, a hole transporting layer, a functional layer having both a hole injecting function and a hole transporting function, a buffer layer, an electron blocking layer, a light emitting layer, a hole blocking layer, an electron transporting layer, And at least one layer selected from the group consisting of functional layers having at the same time.

예를 들어, 상기 이미다졸 유도체는 발광층, 양극과 발광층 사이에 배치된 유기막 및 발광층과 음극 사이에 배치된 유기막으로 이루어진 군 중에서 선택되는 적어도 어느 하나에 포함될 수 있다. 바람직하게는, 상기 이미다졸 유도체는 발광층, 정공주입층, 정공수송층, 및 정공주입 기능과 정공수송 기능을 동시에 갖는 기능층으로 이루어진 군 중에서 선택되는 어느 1층 이상에 포함될 수 있다. 상기 이미다졸 유도체는 단일 물질 또는 서로 다른 물질의 조합으로서 상기 유기막에 포함될 수 있다. 또는 상기 이미다졸 유도체는 발광층, 정공수송층 및 정공주입층 등에 종래 알려진 화합물과 혼합되어 사용될 수 있다. For example, the imidazole derivative may be contained in at least one selected from the group consisting of a light emitting layer, an organic layer disposed between the anode and the light emitting layer, and an organic layer disposed between the light emitting layer and the cathode. Preferably, the imidazole derivative may be contained in at least one layer selected from the group consisting of a light emitting layer, a hole injecting layer, a hole transporting layer, and a functional layer having both a hole injecting function and a hole transporting function. The imidazole derivative may be included in the organic film as a single substance or a combination of different substances. Alternatively, the imidazole derivative may be used in combination with a conventionally known compound such as a light emitting layer, a hole transporting layer, and a hole injecting layer.

본 발명에 따른 유기 전계발광소자는 양극/발광층/음극, 양극/정공주입층/발광층/음극, 양극/정공주입층/정공수송층/발광층/전자수송층/음극, 또는 양극/정공주입층/정공수송층/발광층/전자수송층/전자주입층/음극의 구조를 가질 수 있다. 또는 상기 유기 전계발광소자는 양극/정공주입 기능 및 정공수송 기능을 동시에 갖는 기능층/발광층/전자수송층/음극, 또는 양극/정공주입 기능 및 정공 수송 기능을 동시에 갖는 기능층/발광층/전자수송층/전자주입층/음극의 구조를 가질 수 있지만 이에 한정되는 것은 아니다.The organic electroluminescent device according to the present invention can be applied to an organic electroluminescent device including a positive electrode / a light emitting layer / a cathode, a positive electrode / a hole injecting layer / a light emitting layer / a negative electrode, an anode / a hole injecting layer / a hole transporting layer / a light emitting layer / an electron transporting layer / / Light emitting layer / electron transporting layer / electron injecting layer / cathode structure. Alternatively, the organic electroluminescent device may include a functional layer / a light emitting layer / an electron transporting layer / a cathode having both an anode / hole injecting function and a hole transporting function, a functional layer / a light emitting layer / an electron transporting layer / Electron injecting layer / cathode structure, but the present invention is not limited thereto.

도 1은 본 발명의 일 실시예에 따른 유기 전계발광 소자의 개략적인 단면도이다.1 is a schematic cross-sectional view of an organic electroluminescent device according to an embodiment of the present invention.

상기 유기 전계발광 소자는 스퍼터링(sputtering)이나 전자빔 증발(e-beam evaporation)과 같은 PVD(physical vapor deposition) 방법을 이용하여 제조될 수 있다. 예를 들어, 기판 상에 금속 또는 전도성을 가지는 금속 산화물 또는 이들의 합금을 증착시켜 양극을 형성하고, 그 위에 정공주입층, 정공수송층, 발광층, 전자수송층 및 전자주입층을 포함하는 유기막을 형성한 후, 그 위에 음극으로 사용할 수 있는 물질을 증착시킴으로써 제조될 수 있다. 이와 같은 방법 외에도, 기판 상에 음극 물질부터 유기막, 양극 물질을 차례로 증착시켜 유기 전계발광 소자를 만들 수도 있다.The organic electroluminescent device may be manufactured using a physical vapor deposition (PVD) method such as sputtering or e-beam evaporation. For example, an anode is formed by depositing a metal or a metal oxide having conductivity or an alloy thereof on a substrate, and an organic film including a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer is formed thereon And then depositing a material which can be used as a cathode thereon. In addition to such a method, an organic electroluminescent device may be formed by sequentially depositing a cathode material, an organic film, and a cathode material on a substrate.

한편, 상기 유기막은 다양한 고분자 소재를 사용하여 증착법이 아닌 용액 공정(wet process), 예컨대 스핀 코팅, 딥 코팅, 닥터 블레이딩, 스크린 프린팅, 잉크젯 프린팅 또는 열 전사법 등의 방법으로 제조될 수 있다.Meanwhile, the organic layer may be prepared by a wet process such as spin coating, dip coating, doctor blading, screen printing, inkjet printing, or thermal transfer by using various polymer materials instead of a vapor deposition method.

본 발명에 따른 유기 전계발광 소자는 사용되는 재료에 따라 전면 발광형, 후면 발광형 또는 양면 발광형일 수 있다.
The organic electroluminescent device according to the present invention may be a front emission type, a back emission type, or a both-sided emission type, depending on the material used.

이하, 다양한 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 하나, 이하의 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[실시예] [Example]

중간체합성예Intermediate synthesis example 1 : 중간체(1)의 합성 1: Synthesis of intermediate (1)

Figure 112014105058503-pat00039
Figure 112014105058503-pat00039

500ml 2구 플라스크에 9,10-페난스렌퀴논 (9,10-phenanthrenequinone) 5.0 g(0.024 mol), 4-아이오도아닐린 (4-iodoaniline) 5.8 g(0.026 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 3-피리딘 카복사알데히드 (3-pyridine carboxaldehyde) 2.5 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (1)) 8.9 g(수율: 74 %)을 얻었다.
In a 500 ml two-necked flask, 5.0 g (0.024 mol) of 9,10-phenanthrenequinone, 5.8 g (0.026 mol) of 4-iodoaniline, ammonium acetate, 7.4 g (0.096 mol) of acetic acid and 350 mL of acetic acid were added thereto, followed by stirring. 2.5 ml (0.026 mol) of 3-pyridine carboxaldehyde was added thereto and stirred for 12 hours under reflux. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 8.9 g of a white solid compound (intermediate (1)) (yield: 74%).

중간체합성예Intermediate synthesis example 2 : 중간체(2)의 합성 2: Synthesis of intermediate (2)

Figure 112014105058503-pat00040
Figure 112014105058503-pat00040

500ml 2구 플라스크에 9,10-페난스렌퀴논 (9,10-phenanthrenequinone) 5.0 g(0.024 mol), 4-아이오도아닐린 (4-iodoaniline) 5.8 g(0.026 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 4-피리딘 카복사알데히드 (4-pyridine carboxaldehyde) 2.5 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (2)) 8.4 g(수율: 70 %)을 얻었다.
In a 500 ml two-necked flask, 5.0 g (0.024 mol) of 9,10-phenanthrenequinone, 5.8 g (0.026 mol) of 4-iodoaniline, ammonium acetate, 7.4 g (0.096 mol) of acetic acid and 350 mL of acetic acid were added thereto, followed by stirring. 2.5 ml (0.026 mol) of 4-pyridine carboxaldehyde was added thereto and stirred for 12 hours under reflux. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 8.4 g (yield: 70%) of a white solid compound (intermediate (2)).

중간체합성예Intermediate synthesis example 3 : 중간체(3)의 합성 3: Synthesis of intermediate (3)

Figure 112014105058503-pat00041
Figure 112014105058503-pat00041

500ml 2구 플라스크에 9,10-페난스렌퀴논 (9,10-phenanthrenequinone) 5.0 g(0.024 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 3-피리딘 카복사알데히드 (3-pyridine carboxaldehyde) 2.5 ml(0.026 mol), 3-아이오도아닐린 (3-iodoaniline) 3.1 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (3)) 7.2 g(수율: 60 %)을 얻었다.
5.0 g (0.024 mol) of 9,10-phenanthrenequinone, 7.4 g (0.096 mol) of ammonium acetate and 350 mL of acetic acid were placed in a 500 ml two-necked flask 2.5 ml (0.026 mol) of 3-pyridine carboxaldehyde and 3.1 ml (0.026 mol) of 3-iodoaniline were added thereto while stirring, and the mixture was stirred for 12 hours under reflux. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 7.2 g (yield: 60%) of a white solid compound (intermediate (3)).

중간체합성예Intermediate synthesis example 4 : 중간체(4)의 합성 4: Synthesis of intermediate (4)

Figure 112014105058503-pat00042
Figure 112014105058503-pat00042

500ml 2구 플라스크에 9,10-페난스렌퀴논 (9,10-phenanthrenequinone) 5.0 g(0.024 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 4-피리딘 카복사알데히드 (4-pyridine carboxaldehyde) 2.5 ml(0.026 mol), 3-아이오도아닐린 (3-iodoaniline) 3.1 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (4)) 7.2 g(수율: 60 %)을 얻었다.
5.0 g (0.024 mol) of 9,10-phenanthrenequinone, 7.4 g (0.096 mol) of ammonium acetate and 350 mL of acetic acid were placed in a 500 ml two-necked flask 2.5 ml (0.026 mol) of 4-pyridine carboxaldehyde and 3.1 ml (0.026 mol) of 3-iodoaniline were added to the mixture while stirring, and the mixture was stirred for 12 hours under reflux. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 7.2 g (yield: 60%) of a white solid compound (intermediate (4)).

중간체합성예Intermediate synthesis example 5 : 중간체(5)의 합성 5: Synthesis of intermediate (5)

Figure 112014105058503-pat00043
Figure 112014105058503-pat00043

500ml 2구 플라스크에 벤질 (benzil) 5.0 g(0.024 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 4-피리딘 카복사알데히드 (4-pyridine carboxaldehyde) 2.5 ml(0.026 mol), 3-아이오도아닐린 (3-iodoaniline) 3.1 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (5)) 8.3 g(수율: 70 %)을 얻었다.
5.0 g (0.024 mol) of benzyl, 7.4 g (0.096 mol) of ammonium acetate and 350 mL of acetic acid were added to a 500 ml two-necked flask and stirred with 4-pyridinecarboxaldehyde (4 (0.026 mol) of 3-iodoaniline and 3.1 ml (0.026 mol) of 3-iodoaniline were added to the mixture, followed by stirring for 12 hours under reflux. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 8.3 g (yield: 70%) of a white solid compound (Intermediate (5)).

중간체합성예Intermediate synthesis example 6 : 중간체(6)의 합성 6: Synthesis of intermediate (6)

Figure 112014105058503-pat00044
Figure 112014105058503-pat00044

500ml 2구 플라스크에 벤질 (benzil) 5.0 g(0.024 mol), 4-아이오도아닐린 (4-iodoaniline) 5.7 g(0.026 mol), 암모니늄 아세테이트(ammonium acetate) 7.4 g(0.096 mol), 아세트산(acetic acid) 350 mL를 같이 넣고 교반하다가 3-피리딘 카복사알데히드 (3-pyridine carboxaldehyde) 2.5 ml(0.026 mol)를 첨가하고, 가열 환류하에 12시간 교반하였다. 종결된 후 상온으로 냉각하고, 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 용매를 증류 제거했다. 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체 화합물 (중간체 (6)) 8.3 g(수율: 70 %)을 얻었다.
In a 500 ml two-necked flask, 5.0 g (0.024 mol) of benzyl, 5.7 g (0.026 mol) of 4-iodoaniline, 7.4 g (0.096 mol) of ammonium acetate, acid, and 2.5 ml (0.026 mol) of 3-pyridine carboxaldehyde were added thereto under stirring. The mixture was stirred under reflux for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and the solvent was distilled off. The residue was purified by silica gel column chromatography to obtain 8.3 g (yield: 70%) of a white solid compound (intermediate (6)).

실시예 1 : 화합물(4-1)의 합성Example 1: Synthesis of compound (4-1)

화합물(4-1)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-1) is shown below.

Figure 112014105058503-pat00045
Figure 112014105058503-pat00045

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 벤조티오펜 델타-카볼린 (benzothiophene d-carboline) 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120-130 에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-1) 0.4 g (수율: 60%)을 얻었다.
(1) (0.5 g, 1.005 mmol), benzothiophene d-carboline 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Then, the mixture was stirred at 120-130 for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.4 g (yield: 60%) of a white solid compound (4-1).

실시예 2 : 화합물(4-2)의 합성Example 2: Synthesis of compound (4-2)

화합물(4-2)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-2) is shown below.

Figure 112014105058503-pat00046
Figure 112014105058503-pat00046

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 벤조 델타-카볼린 (benzo d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-2) 0.4 g (수율: 60%)을 얻었다.
(1) (0.5 g, 1.005 mmol), benzo d-carboline 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-phenanthrene Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.4 g (yield: 60%) of a white solid compound (4-2).

실시예 3 : 화합물(4-3)의 합성Example 3: Synthesis of compound (4-3)

화합물(4-3)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-3) is shown below.

Figure 112014105058503-pat00047
Figure 112014105058503-pat00047

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 이미다졸 델타-카볼린 (imidazole d-carboline) 0.4 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-3) 0.3 g (수율: 45%)을 얻었다.
(1) (0.5 g, 1.005 mmol), imidazole d-carboline (0.4 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and dimethylformamide (DMF) , And the mixture was stirred at 120 to 130 ° C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-3) (yield: 45%).

실시예 4 : 화합물(4-4)의 합성Example 4: Synthesis of compound (4-4)

화합물(4-4)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-4) is shown below.

Figure 112014105058503-pat00048
Figure 112014105058503-pat00048

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 베타-카볼린 (b-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-4) 27 mg (수율: 5%)을 얻었다.
(1) (0.5 g, 1.005 mmol), b-carboline 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), and 1,10-phenanthroline Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 27 mg (yield: 5%) of a white solid compound (4-4).

실시예 5 : 화합물(4-5)의 합성Example 5: Synthesis of compound (4-5)

화합물(4-5)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-5) is shown below.

Figure 112014105058503-pat00049
Figure 112014105058503-pat00049

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 벤조푸로 델타-카볼린 (benzofuro d-carboline) 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-5) 0.3 g (수율: 40%)을 얻었다.
(1) (0.5 g, 1.005 mmol), benzofuro d-carboline (0.3 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and dimethylformamide (DMF) , And the mixture was stirred at 120 to 130 ° C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-5) (yield: 40%).

실시예 6 : 화합물(4-6)의 합성Example 6: Synthesis of compound (4-6)

화합물(4-6)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-6) is shown below.

Figure 112014105058503-pat00050
Figure 112014105058503-pat00050

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 알파-카볼린 (a-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-6) 0.2 g (수율: 45%)을 얻었다.
(1) (0.5 g, 1.005 mmol), a-carboline 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol) and 1,10-phenanthroline Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-6) (yield: 45%).

실시예 7 : 화합물(4-7)의 합성Example 7: Synthesis of compound (4-7)

화합물(4-7)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-7) is shown below.

Figure 112014105058503-pat00051
Figure 112014105058503-pat00051

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 11-벤조 델타-카볼린 (11-benzo d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-7) 0.2 g (수율: 30%)을 얻었다.
(1) (0.5 g, 1.005 mmol), 11-benzo d-carboline (0.2 g, 1.105 mmol) and CuI (24 mg, 0.126 mmol) A mixture of 45 mg (0.251 mmol) of 10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) After mixing, the mixture was stirred at 120 to 130 ° C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-7) (yield: 30%).

실시예 8 : 화합물(4-8)의 합성Example 8: Synthesis of compound (4-8)

화합물(4-8)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-8) is shown below.

Figure 112014105058503-pat00052
Figure 112014105058503-pat00052

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 디페닐아미노 델타-카볼린 (diphenylamino d-carboline) 0.4 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-8) 0.3 g (수율: 45%)을 얻었다.
(1) (0.5 g, 1.005 mmol), diphenylamino d-carboline (0.4 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Then, the mixture was stirred at 120 to 130 ° C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-8) (yield: 45%).

실시예 9 : 화합물(4-9)의 합성Example 9: Synthesis of compound (4-9)

화합물(4-9)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-9) is shown below.

Figure 112014105058503-pat00053
Figure 112014105058503-pat00053

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 7-티-부틸 델타-카볼린 (7-t-butyl d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-9) 0.2 g (수율: 40%)을 얻었다.
(1) (0.5 g, 1.005 mmol), 7-t-butyl d-carboline (0.2 g, 1.105 mmol) and CuI (24 mg, 0.126 mmol ), 1,10-phenanthroline 45 mg (0.251 mmol), cesium carbonate (Cs 2 CO 3 ) 0.7 g (2.010 mmol) and dimethylformamide (DMF) 40 mL), and then stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-9) (yield: 40%).

실시예 10 : 화합물(4-10)의 합성Example 10: Synthesis of compound (4-10)

화합물(4-10)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-10) is shown below.

Figure 112014105058503-pat00054
Figure 112014105058503-pat00054

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 델타-카볼린 (d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-10) 0.2 g (수율: 40%)을 얻었다.
(1) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of d-carboline, 24 mg (0.126 mmol) of CuI and 1,10-phenanthroline Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-10) (yield: 40%).

실시예Example 11 : 화합물(4-11)의 합성 11: Synthesis of compound (4-11)

화합물(4-11)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-11) is shown below.

Figure 112014105058503-pat00055
Figure 112014105058503-pat00055

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 이미다졸 보레이트 (imidazole borate) (0.4 g, 1.105 mmol), Pd(PPh3)4 35 mg (0.030 mmol), toluene (40 mL)와 같이 넣고 교반하다가 에탄올(ethanol) (20 mL), K2CO3 0.2 g (1.508 mmol)/ H2O (20 mL)를 첨가하고, 가열 환류하에 6시간 교반하였다. 반응이 종결되면 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-11) 0.3 g (수율: 50%)을 얻었다.
In 1 100 mL flask, intermediate (1) (0.5 g, 1.005 mmol), imidazole borate (imidazole borate) (0.4 g, 1.105 mmol), Pd (PPh 3) 4 35 mg (0.030 mmol), toluene (40 mL (20 mL) and K 2 CO 3 0.2 g (1.508 mmol) / H 2 O (20 mL) were added to the solution, and the mixture was stirred under reflux for 6 hours. After the reaction was completed, water was added and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and purified by silica gel column chromatography to obtain 0.3 g (yield: 50%) of a white solid compound (4-11) ≪ / RTI >

실시예 12 : 화합물(4-12)의 합성Example 12: Synthesis of compound (4-12)

화합물(4-12)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-12) is shown below.

Figure 112014105058503-pat00056
Figure 112014105058503-pat00056

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 트라이페닐아민-4-보레이트 (triphenylamine 4-borate) (0.4 g, 1.105 mmol), Pd(PPh3)4 35 mg (0.030 mmol), 톨루엔(toluene) (40 mL)와 같이 넣고 교반하다가 에탄올(ethanol) (20 mL), K2CO3 0.2 g (1.508 mmol)/ H2O (20 mL)를 첨가하고, 가열 환류하에 6시간 교반하였다. 반응이 종결되면 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-12) 0.3 g (수율: 50%)을 얻었다.
Intermediate 1 to obtain 100 mL flask (1) (0.5 g, 1.005 mmol), triphenyl borate-4-amine (triphenylamine 4-borate) (0.4 g, 1.105 mmol), Pd (PPh 3) 4 35 mg (0.030 mmol (20 mL) and K 2 CO 3 (0.25 g, 1.508 mmol) / H 2 O (20 mL) were added to the solution, and the mixture was stirred under reflux for 6 Lt; / RTI > After the reaction was completed, water was added, and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and purified by silica gel column chromatography to obtain 0.3 g (yield: 50%) of a white solid compound (4-12) ≪ / RTI >

실시예 13 : 화합물(4-13)의 합성Example 13: Synthesis of compound (4-13)

화합물(4-13)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-13) is shown below.

Figure 112014105058503-pat00057
Figure 112014105058503-pat00057

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 카바졸 (carbazole) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-13) 0.3 g (수율: 60%)을 얻었다.
(1) (0.5 g, 1.005 mmol), carbazole 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-phenanthroline phenanthroline (45 mg, 0.251 mmol), cesium carbonate (Cs 2 CO 3 ) (0.7 g, 2.010 mmol) and dimethylformamide (DMF) Lt; / RTI > After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-13) (yield: 60%).

실시예 14 : 화합물(4-14)의 합성Example 14: Synthesis of compound (4-14)

화합물(4-14)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-14) is shown below.

Figure 112014105058503-pat00058
Figure 112014105058503-pat00058

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 4-(페닐아미노)벤조니트릴 (4-(phenylamino)benzonitrile) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-14) 0.2 g (수율: 35%)을 얻었다.
(1) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of 4- (phenylamino) benzonitrile, 24 mg (0.126 mmol) of CuI, , 45 mg (0.251 mmol) of 10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-14) (yield: 35%).

실시예 15 : 화합물(4-15)의 합성Example 15: Synthesis of compound (4-15)

화합물(4-15)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-15) is shown below.

Figure 112014105058503-pat00059
Figure 112014105058503-pat00059

1구 100 mL 플라스크에 중간체(1) (0.5 g, 1.005 mmol), 디페닐아민 (diphenylamine) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-15) 0.1 g (수율: 20%)을 얻었다.
(1) (0.5 g, 1.005 mmol), diphenylamine 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-phenanthroline was mixed with 45 mg (0.251 mmol) of phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Stir for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.1 g (yield: 20%) of a white solid compound (4-15).

실시예 16 : 화합물(4-16)의 합성Example 16: Synthesis of compound (4-16)

화합물(4-16)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-16) is shown below.

Figure 112014105058503-pat00060
Figure 112014105058503-pat00060

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 벤조 델타-카볼린 (benzo d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-16) 0.4 g (수율: 60%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), benzo d-carboline 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol) Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.4 g (yield: 60%) of a white solid compound (4-16).

실시예 17 : 화합물(4-17)의 합성Example 17: Synthesis of compound (4-17)

화합물(4-17)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-17) is shown below.

Figure 112014105058503-pat00061
Figure 112014105058503-pat00061

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 벤조티오펜 델타-카볼린 (benzothiophene d-carboline) 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-17) 0.2 g (수율: 30%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), benzothiophene d-carboline 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol) Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Then, the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 30%) of a white solid compound (4-17).

실시예 18 : 화합물(4-18)의 합성Example 18: Synthesis of compound (4-18)

화합물(4-18)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-18) is shown below.

Figure 112014105058503-pat00062
Figure 112014105058503-pat00062

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 벤조푸로 델타-카볼린 (benzofuro d-carboline) 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-18) 0.2 g (수율: 35%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), benzofuro d-carboline 0.3 g (1.105 mmol), CuI 24 mg (0.126 mmol) Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and dimethylformamide (DMF) , And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-18) (yield: 35%).

실시예 19 : 화합물(4-19)의 합성Example 19: Synthesis of compound (4-19)

화합물(4-19)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-19) is shown below.

Figure 112014105058503-pat00063
Figure 112014105058503-pat00063

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 델타-카볼린 (d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(1-19) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of d-carboline, 24 mg (0.126 mmol) CuI, Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 40%) of a white solid compound (1-19).

실시예Example 20 : 화합물(4-20)의 합성 20: Synthesis of compound (4-20)

화합물(4-20)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-20) is shown below.

Figure 112014105058503-pat00064
Figure 112014105058503-pat00064

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 디페닐아미노 델타-카볼린 (diphenylamino d-carboline) 0.4 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-20) 0.3 g (수율: 45%)을 얻었다.
(0.5 g, 1.005 mmol), diphenylamino d-carboline (0.4 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Then, the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-20) (yield: 45%).

실시예 21 : 화합물(4-21)의 합성Example 21: Synthesis of compound (4-21)

화합물(4-21)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-21) is shown below.

Figure 112014105058503-pat00065
Figure 112014105058503-pat00065

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 11-벤조 델타-카볼린 (11-benzo d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-21) 0.2 g (수율: 30%)을 얻었다.
(0.5 g, 1.005 mmol), 11-benzo d-carboline (0.2 g, 1.105 mmol), CuI (24 mg, 0.126 mmol) A mixture of 45 mg (0.251 mmol) of 10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) After mixing, the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-21) (yield: 30%).

실시예 22 : 화합물(4-22)의 합성Example 22: Synthesis of compound (4-22)

화합물(4-22)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-22) is shown below.

Figure 112014105058503-pat00066
Figure 112014105058503-pat00066

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 알파-카볼린 (a-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-22) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), a-carboline 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-phenanthroline Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 40%) of a white solid compound (4-22).

실시예 23 : 화합물(4-23)의 합성Example 23: Synthesis of compound (4-23)

화합물(4-23)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-23) is shown below.

Figure 112014105058503-pat00067
Figure 112014105058503-pat00067

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 이미다졸 델타-카볼린 (imidazole d-carboline) 0.4 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-23) 0.4 g (수율: 50%)을 얻었다.
(0.5 g, 1.005 mmol), imidazole d-carboline (0.4 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and dimethylformamide (DMF) , And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.4 g (yield: 50%) of a white solid compound (4-23).

실시예 24 : 화합물(4-24)의 합성Example 24: Synthesis of compound (4-24)

화합물(4-24)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-24) is shown below.

Figure 112014105058503-pat00068
Figure 112014105058503-pat00068

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 베타-카볼린 (b-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-24) 38 mg (수율: 7%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of b-carboline, 24 mg (0.126 mmol) CuI, Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 38 mg (yield: 7%) of a white solid compound (4-24).

실시예 25 : 화합물(4-25)의 합성Example 25: Synthesis of compound (4-25)

화합물(4-25)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-25) is shown below.

Figure 112014105058503-pat00069
Figure 112014105058503-pat00069

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 7-티-부틸 델타-카볼린 (7-t-butyl d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-25) 0.3 g (수율: 50%)을 얻었다.
(0.5 g, 1.005 mmol), 7-t-butyl d-carboline (0.2 g, 1.105 mmol) and CuI (24 mg, 0.126 mmol) ), 1,10-phenanthroline 45 mg (0.251 mmol), cesium carbonate (Cs 2 CO 3 ) 0.7 g (2.010 mmol) and dimethylformamide (DMF) 40 mL), and then stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-25) (yield: 50%).

실시예 26 : 화합물(4-26)의 합성Example 26: Synthesis of compound (4-26)

화합물(4-26)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-26) is shown below.

Figure 112014105058503-pat00070
Figure 112014105058503-pat00070

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 카바졸 (carbazole) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-26) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (2) (0.5 g, 1.005 mmol), carbazole 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10- phenanthroline (45 mg, 0.251 mmol), cesium carbonate (Cs 2 CO 3 ) (0.7 g, 2.010 mmol) and dimethylformamide (DMF) Lt; / RTI > After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 40%) of a white solid compound (4-26).

실시예 27 : 화합물(4-27)의 합성Example 27: Synthesis of compound (4-27)

화합물(4-27)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-27) is shown below.

Figure 112014105058503-pat00071
Figure 112014105058503-pat00071

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 4-(페닐아미노)벤조니트릴 (4-(phenylamino)benzonitrile) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-27) 0.2 g (수율: 40%)을 얻었다.
(0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of 4- (phenylamino) benzonitrile, 24 mg (0.126 mmol) of CuI, , 45 mg (0.251 mmol) of 10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 40%) of a white solid compound (4-27).

실시예 28 : 화합물(4-28)의 합성Example 28: Synthesis of compound (4-28)

화합물(4-28)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-28) is shown below.

Figure 112014105058503-pat00072
Figure 112014105058503-pat00072

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 디페닐아민 (diphenylamine) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-28) 0.2 g (수율: 40%)을 얻었다.
(0.5 g, 1.005 mmol), diphenylamine (0.2 g, 1.105 mmol), CuI (24 mg, 0.126 mmol), 1,10-phenanthroline was mixed with 45 mg (0.251 mmol) of phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Stir for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g (yield: 40%) of a white solid compound (4-28).

실시예 29 : 화합물(4-29)의 합성Example 29: Synthesis of compound (4-29)

화합물(4-29)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-29) is shown below.

Figure 112014105058503-pat00073
Figure 112014105058503-pat00073

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 트라이페닐아민-4-보레이트 (triphenylamine 4-borate) (0.4 g, 1.105 mmol), Pd(PPh3)4 35 mg (0.030 mmol), 톨루엔(toluene) (40 mL)와 같이 넣고 교반하다가 에탄올(ethanol) (20 mL), K2CO3 0.2 g (1.508 mmol)/ H2O (20 mL)를 첨가하고, 가열 환류하에 6시간 교반하였다. 반응이 종결되면 물을 첨가 후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-29) 0.3 g (수율: 50%)을 얻었다.
Intermediate 1 to obtain 100 mL flask (2) (0.5 g, 1.005 mmol), triphenyl borate-4-amine (triphenylamine 4-borate) (0.4 g, 1.105 mmol), Pd (PPh 3) 4 35 mg (0.030 mmol (20 mL) and K 2 CO 3 (0.25 g, 1.508 mmol) / H 2 O (20 mL) were added to the solution, and the mixture was stirred under reflux for 6 Lt; / RTI > After the reaction was completed, water was added and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and purified by silica gel column chromatography to obtain 0.3 g (yield: 50%) of a white solid compound (4-29) ≪ / RTI >

실시예Example 30 : 화합물(4-30)의 합성 30: Synthesis of compound (4-30)

화합물(4-30)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-30) is shown below.

Figure 112014105058503-pat00074
Figure 112014105058503-pat00074

1구 100 mL 플라스크에 중간체(2) (0.5 g, 1.005 mmol), 이미다졸 보레이트 (imidazole borate) (0.4 g, 1.105 mmol), Pd(PPh3)4 35 mg (0.030 mmol), 톨루엔(toluene) (40 mL)와 같이 넣고 교반하다가 에탄올(ethanol) (20 mL), K2CO3 0.2 g (1.508 mmol)/ H2O (20 mL)를 첨가하고, 가열 환류하에 6시간 교반하였다. 반응이 종결되면 물을 첨가후 메틸렌클로라이드(methylene chloride)로 추출하고 유기상을 무수 MgSO4로 건조하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-30) 0.3 g (수율: 50%)을 얻었다.
In 1 100 mL flask, intermediate (2) (0.5 g, 1.005 mmol), imidazole borate (imidazole borate) (0.4 g, 1.105 mmol), Pd (PPh 3) 4 35 mg (0.030 mmol), toluene (toluene) (20 mL) and K 2 CO 3 (0.20 g, 1.508 mmol) / H 2 O (20 mL) were added to the solution, and the mixture was stirred under reflux for 6 hours. After the reaction was completed, water was added and the mixture was extracted with methylene chloride. The organic phase was dried over anhydrous MgSO 4 and purified by silica gel column chromatography to obtain 0.3 g (yield: 50%) of a white solid (4-30) ≪ / RTI >

실시예 31 : 화합물(4-31)의 합성Example 31: Synthesis of compound (4-31)

화합물(4-31)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-31) is shown below.

Figure 112014105058503-pat00075
Figure 112014105058503-pat00075

1구 100 mL 플라스크에 중간체(3) (0.5 g, 1.005 mmol), 델타-카볼린 (d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-31) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (3) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of d-carboline, 24 mg (0.126 mmol) CuI, Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-31) (yield: 40%).

실시예 32 : 화합물(4-32)의 합성Example 32: Synthesis of compound (4-32)

화합물(4-32)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-32) is shown below.

Figure 112014105058503-pat00076
Figure 112014105058503-pat00076

1구 100 mL 플라스크에 중간체(3) (0.5 g, 1.005 mmol), 카바졸 (carbazole) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-32) 0.2 g (수율: 35%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (3) (0.5 g, 1.005 mmol), carbazole 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10- phenanthroline (45 mg, 0.251 mmol), cesium carbonate (Cs 2 CO 3 ) (0.7 g, 2.010 mmol) and dimethylformamide (DMF) Lt; / RTI > After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-32) (yield: 35%).

실시예 33 : 화합물(4-33)의 합성Example 33: Synthesis of compound (4-33)

화합물(4-33)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-33) is shown below.

Figure 112014105058503-pat00077
Figure 112014105058503-pat00077

1구 100 mL 플라스크에 중간체(4) (0.5 g, 1.005 mmol), 델타-카볼린 (d-carboline) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-33) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (4) (0.5 g, 1.005 mmol), 0.2 g (1.105 mmol) of d-carboline, 24 mg (0.126 mmol) CuI, Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) And the mixture was stirred at 130 DEG C for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-33) (yield: 40%).

실시예 34 : 화합물(4-34)의 합성Example 34: Synthesis of compound (4-34)

화합물(4-34)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-34) is shown below.

Figure 112014105058503-pat00078
Figure 112014105058503-pat00078

1구 100 mL 플라스크에 중간체(4) (0.5 g, 1.005 mmol), 카바졸 (carbazole) 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.010 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120-130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-34) 0.2 g (수율: 40%)을 얻었다.
A 1-necked 100 mL flask was charged with Intermediate 4 (0.5 g, 1.005 mmol), carbazole 0.2 g (1.105 mmol), CuI 24 mg (0.126 mmol), 1,10-phenanthroline phenanthroline), 0.7 g (2.010 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) (40 mL) Lt; / RTI > After completion of the reaction, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.2 g of a white solid (4-34) (yield: 40%).

실시예 35 : 화합물(4-35)의 합성Example 35: Synthesis of compound (4-35)

화합물(4-35)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-35) is shown below.

Figure 112014105058503-pat00079
Figure 112014105058503-pat00079

1구 100 mL 플라스크에 중간체(5) (0.5 g, 1.002 mmol), 디페닐아미노 델타-카볼린 (diphenylamino d-carboline) 0.4 g (1.102 mmol), CuI 24 mg (0.125 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.004 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-35) 0.4 g (수율: 60%)을 얻었다.
(0.5 g, 1.002 mmol), diphenylamino d-carboline (0.4 g, 1.102 mmol), CuI (24 mg, 0.125 mmol), 1,10- Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.004 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) Then, the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.4 g of a white solid (4-35) (yield: 60%).

실시예 36 : 화합물(4-36)의 합성Example 36: Synthesis of compound (4-36)

화합물(4-36)의 합성 경로를 이하에 나타낸다.The synthesis route of the compound (4-36) is shown below.

Figure 112014105058503-pat00080
Figure 112014105058503-pat00080

1구 100 mL 플라스크에 중간체(6) (0.5 g, 1.002 mmol), 벤조푸로 델타-카볼린 (benzofuro d-carboline) 0.3 g (1.102 mmol), CuI 24 mg (0.125 mmol), 1,10-페난스롤린 (1,10-phenanthroline) 45 mg (0.251 mmol), 세슘카보네이트 (cesium carbonate, Cs2CO3) 0.7 g (2.004 mmol) 및 디메틸포름아미드(dimethylformamide, DMF) (40 mL)와 혼합한 다음, 120~130℃에서 12시간 동안 교반하였다. 반응이 종결된 후 상온으로 냉각하고, 실리카겔 컬럼 크로마토그래피로 정제하여 흰색 고체의 화합물(4-36) 0.3 g (수율: 45%)을 얻었다.
A 1-necked 100 mL flask was charged with intermediate (6) (0.5 g, 1.002 mmol), benzofuro d-carboline (0.3 g, 1.102 mmol), CuI (24 mg, 0.125 mmol) Was mixed with 45 mg (0.251 mmol) of 1,10-phenanthroline, 0.7 g (2.004 mmol) of cesium carbonate (Cs 2 CO 3 ) and 40 mL of dimethylformamide (DMF) , And the mixture was stirred at 120 to 130 ° C for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and purified by silica gel column chromatography to obtain 0.3 g of a white solid (4-36) (yield: 45%).

<시험예 1>&Lt; Test Example 1 >

본 발명의 화합물에 대하여 Jasco V-630 기기를 이용하여 UV/VIS 스펙트럼을 측정하고, Jasco FP-8500 기기를 이용하여 PL(photoluminescence) 스펙트럼을 측정하여 하기 표 1에 나타내었다.
The UV / VIS spectra of the compounds of the present invention were measured using a Jasco V-630 instrument and PL (photoluminescence) spectra were measured using a Jasco FP-8500 instrument.

화합물들의 UV/VIS 및 PL 결과UV / VIS and PL results of compounds 구분(화합물)Classification (compound) UV/VIS (nm)*1UV / VIS (nm) * 1 PL(nm, 상온)*2PL (nm, room temperature) * 2 실시예 1 (화합물 4-1)Example 1 (Compound 4-1) 252, 261, 283, 310, 345, 361252, 261, 283, 310, 345, 361 386.5386.5 실시예 2 (화합물 4-2)Example 2 (Compound 4-2) 259, 326259, 326 374.5, 392374.5, 392 실시예 3 (화합물 4-3)Example 3 (Compound 4-3) 261, 327261, 327 380, 397380, 397 실시예 4 (화합물 4-4)Example 4 (Compound 4-4) 270270 370.5, 388.5370.5, 388.5 실시예 5 (화합물 4-5)Example 5 (Compound 4-5) 244, 260, 292, 300, 344, 359244, 260, 292, 300, 344, 359 386.5386.5 실시예 6 (화합물 4-6)Example 6 (Compound 4-6) 261, 292, 360261, 292, 360 370.5, 388.5370.5, 388.5 실시예 7 (화합물 4-7)Example 7 (Compound 4-7) 258, 309, 360258, 309, 360 393393 실시예 8 (화합물 4-8)Example 8 (Compound 4-8) 261, 345, 361261, 345, 361 431431 실시예 9 (화합물 4-9)Example 9 (Compound 4-9) 260, 304, 359260, 304, 359 370.5, 388370.5, 388 실시예 10 (화합물 4-10)Example 10 (Compound 4-10) 261, 300, 359261, 300, 359 370.5, 388.5370.5, 388.5 실시예 11 (화합물 4-11)Example 11 (Compound 4-11) 261, 314261, 314 371.5, 389.5371.5, 389.5 실시예 12 (화합물 4-12)Example 12 (Compound 4-12) 261, 290, 344261, 290, 344 431.5431.5 실시예 13 (화합물 4-13)Example 13 (Compound 4-13) 244, 252, 260, 291, 305, 359244, 252, 260, 291, 305, 359 370.5, 388.5370.5, 388.5 실시예 14 (화합물 4-14)Example 14 (Compound 4-14) 262, 329262, 329 417.5417.5 실시예 15 (화합물 4-15)Example 15 (Compound 4-15) 261, 307, 360261, 307, 360 371.5, 391, 411.5371.5, 391, 411.5 실시예 16 (화합물 4-16)Example 16 (Compound 4-16) 259, 328, 362259, 328, 362 400.5400.5 실시예 17 (화합물 4-17)Example 17 (Compound 4-17) 251, 261, 282, 302, 310, 346, 362251, 261, 282, 302, 310, 346, 362 399.5399.5 실시예 18 (화합물 4-18)Example 18 (Compound 4-18) 244, 262, 293, 300, 308, 332, 345, 360244, 262, 293, 300, 308, 332, 345, 360 400.5400.5 실시예 19 (화합물 4-19)Example 19 (Compound 4-19) 261, 300, 331, 343, 361261, 300, 331, 343, 361 402.5402.5 실시예 20 (화합물 4-20)Example 20 (Compound 4-20) 242, 261, 332, 347, 363242, 261, 332, 347, 363 432432 실시예 21 (화합물 4-21)Example 21 (Compound 4-21) 253, 307, 343, 361253, 307, 343, 361 403.5403.5 실시예 22 (화합물 4-22)Example 22 (Compound 4-22) 245, 261, 295, 331, 362245, 261, 295, 331, 362 403403 실시예 23 (화합물 4-23)Example 23 (Compound 4-23) 252, 260, 305, 330252, 260, 305, 330 400400 실시예 24 (화합물 4-24)Example 24 (Compound 4-24) 247, 287, 346, 361247, 287, 346, 361 403.5403.5 실시예 25 (화합물 4-25)Example 25 (Compound 4-25) 253, 260, 303, 330, 361253, 260, 303, 330, 361 402.5402.5 실시예 26 (화합물 4-26)Example 26 (Compound 4-26) 243, 260, 284, 291, 324, 362243, 260, 284, 291, 324, 362 402.5402.5 실시예 27 (화합물 4-27)Example 27 (Compound 4-27) 262, 333262, 333 409.5409.5 실시예 28 (화합물 4-28)Example 28 (Compound 4-28) 262, 305, 363262, 305, 363 456456 실시예 29 (화합물 4-29)Example 29 (Compound 4-29) 261, 294, 346261, 294, 346 436436 실시예 30 (화합물 4-30)Example 30 (Compound 4-30) 261, 315, 360261, 315, 360 402.5402.5 실시예 31 (화합물 4-31)Example 31 (Compound 4-31) 261, 292, 298, 325, 358261, 292, 298, 325, 358 371, 388371, 388 실시예 32 (화합물 4-32)Example 32 (Compound 4-32) 243, 260, 290, 359243, 260, 290, 359 370.5, 388370.5, 388 실시예 33 (화합물 4-33)Example 33 (Compound 4-33) 261, 295, 331, 342, 361261, 295, 331, 342, 361 402.5402.5 실시예 34 (화합물 4-34)Example 34 (Compound 4-34) 242, 260, 283, 291, 326, 361242, 260, 283, 291, 326, 361 402402 실시예 35 (화합물 4-35)Example 35 (Compound 4-35) 233, 262, 371233, 262, 371 431.5431.5 실시예 36 (화합물 4-36)Example 36 (Compound 4-36) 242, 272, 300, 346, 360242, 272, 300, 346, 360 386386 *1 : 1.0 x 10-5 M in 메틸렌클로라이드(methylene chloride)
*2 : 5.0 x 10-6 M in 메틸렌클로라이드(methylene chloride)
* 1: 1.0 x 10 -5 M in methylene chloride
* 2: 5.0 x 10 -6 M in methylene chloride

본 발명의 화합물에 대하여 Waters Acquity UPLC H-Class/ SQD2 system 기기를 이용하여 LC-MS를 측정하였으며 그 결과를 하기 표 2에 나타내었다.
The compounds of the present invention were analyzed by LC-MS using a Waters Acquity UPLC H-Class / SQD2 system instrument and the results are shown in Table 2 below.

화합물들의 LC/MS 결과 LC / MS results of the compounds 구분(화합물)Classification (compound) MS Calcd.MS Calcd. LC-MS Found [M+1]+LC-MS Found [M + 1] &lt; + &gt; 실시예 1 (화합물 4-1)Example 1 (Compound 4-1) 643.76643.76 644.39644.39 실시예 2 (화합물 4-2)Example 2 (Compound 4-2) 587.67587.67 588.44588.44 실시예 3 (화합물 4-3)Example 3 (Compound 4-3) 729.83729.83 730.54730.54 실시예 4 (화합물 4-4)Example 4 (Compound 4-4) 537.61537.61 538.41538.41 실시예 5 (화합물 4-5)Example 5 (Compound 4-5) 627.69627.69 628.42628.42 실시예 6 (화합물 4-6)Example 6 (Compound 4-6) 537.61537.61 538.21538.21 실시예 7 (화합물 4-7)Example 7 (Compound 4-7) 587.67587.67 588.24588.24 실시예 8 (화합물 4-8)Example 8 (Compound 4-8) 704.82704.82 705.53705.53 실시예 9 (화합물 4-9)Example 9 (Compound 4-9) 593.72593.72 594.43594.43 실시예 10 (화합물 4-10)Example 10 (Compound 4-10) 537.61537.61 538.14538.14 실시예 11 (화합물 4-11)Example 11 (Compound 4-11) 639.75639.75 640.27640.27 실시예 12 (화합물 4-12)Example 12 (Compound 4-12) 614.74614.74 615.45615.45 실시예 13 (화합물 4-13)Example 13 (Compound 4-13) 536.62536.62 537.41537.41 실시예 14 (화합물 4-14)Example 14 (Compound 4-14) 563.65563.65 564.35564.35 실시예 15 (화합물 4-15)Example 15 (Compound 4-15) 538.64538.64 539.14539.14 실시예 16 (화합물 4-16)Example 16 (Compound 4-16) 587.67587.67 588.17588.17 실시예 17 (화합물 4-17)Example 17 (Compound 4-17) 643.76643.76 644.46644.46 실시예 18 (화합물 4-18)Example 18 (Compound 4-18) 627.69627.69 628.42628.42 실시예 19 (화합물 4-19)Example 19 (Compound 4-19) 537.61537.61 538.41538.41 실시예 20 (화합물 4-20)Example 20 (Compound 4-20) 704.82704.82 705.53705.53 실시예 21 (화합물 4-21)Example 21 (Compound 4-21) 587.67587.67 588.24588.24 실시예 22 (화합물 4-22)Example 22 (Compound 4-22) 537.61537.61 538.21538.21 실시예 23 (화합물 4-23)Example 23 (Compound 4-23) 729.83729.83 730.54730.54 실시예 24 (화합물 4-24)Example 24 (Compound 4-24) 537.61537.61 538.41538.41 실시예 25 (화합물 4-25)Example 25 (Compound 4-25) 593.72593.72 594.43594.43 실시예 26 (화합물 4-26)Example 26 (Compound 4-26) 536.62536.62 537.41537.41 실시예 27 (화합물 4-27)Example 27 (Compound 4-27) 563.65563.65 564.42564.42 실시예 28 (화합물 4-28)Example 28 (Compound 4-28) 538.64538.64 539.40539.40 실시예 29 (화합물 4-29)Example 29 (Compound 4-29) 614.74614.74 615.32615.32 실시예 30 (화합물 4-30)Example 30 (Compound 4-30) 639.75639.75 640.27640.27 실시예 31 (화합물 4-31)Example 31 (Compound 4-31) 537.61537.61 538.27538.27 실시예 32 (화합물 4-32)Example 32 (Compound 4-32) 536.62536.62 537.34537.34 실시예 33 (화합물 4-33)Example 33 (Compound 4-33) 537.61537.61 538.34538.34 실시예 34 (화합물 4-34)Example 34 (Compound 4-34) 536.62536.62 537.34537.34 실시예 35 (화합물 4-35)Example 35 (Compound 4-35) 706.83706.83 707.79707.79 실시예 36 (화합물 4-36)Example 36 (Compound 4-36) 629.71629.71 630.69630.69

소자 제작 Device fabrication 시험예Test Example

소자 제작을 위해 투명 전극인 ITO는 양극 층으로 사용하였고, 2-TNATA는 정공 주입층, NPB는 정공 수송층, -ADN은 발광층의 호스트, Bphen 은 전자 수송층, Liq는 전자 주입층, Al은 음극으로 사용하였다. 이 화합물들의 구조는 하기의 화학식과 같다.2-TNATA is a hole injection layer, NPB is a hole transport layer, -ADN is a host of a light emitting layer, Bphen is an electron transport layer, Liq is an electron injection layer, and Al is a cathode. Respectively. The structures of these compounds are shown below.

Figure 112014105058503-pat00081

Figure 112014105058503-pat00081

비교시험예Comparative test example :  : ITOITO / 2- / 2- TNATATNATA /  / NPBNPB / αβ- / αβ- ADNADN , 9,9-, 9,9- diethyldiethyl -2,7-bis((E)-4-tritylstyryl)-9H-fluorene / -2,7-bis ((E) -4-tritylstyryl) -9H-fluorene / BphenBphen /  / LiqLiq /  / AlAl

청색 형광 유기발광소자는 ITO(180 nm) / 2-TNATA (60 nm) / NPB (20 nm) / αβ-ADN : 9,9-diethyl-2,7-bis((E)-4-tritylstyryl)-9H-fluorene 10% (30 nm) / Bphen (40 nm) / Liq (2 nm) / Al (100 nm) 순으로 증착하여 소자를 제작하였다. 유기물을 증착하기 전에 ITO 전극은 2×10-2Torr에서 125 W로 2분간 산소 플라즈마 처리를 하였다. 유기물은 9×10-7Torr의 진공도에서 증착하였으며 Liq는 0.1 Å/sec, αβ-ADN은 0.18 Å/sec의 기준으로 청색 형광 도판트는 0.02 Å/sec으로 동시 증착하였고, 나머지 유기물들은 모두 1 Å/sec의 속도로 증착하였다. 실험에 사용 된 청색 형광 도판트 물질은 9,9-diethyl-2,7-bis((E)-4-tritylstyryl)-9H-fluorene 이며, 도판트의 농도는 10%로 고정하였다. 소자 제작이 끝난 후 소자의 공기 및 수분의 접촉을 막기 위하여 질소 기체로 채워져 있는 글러브 박스 안에서 봉지를 하였다. 3M사의 접착용 테이프로 격벽을 형성 후 수분 등을 제거할 수 있는 흡습제인 바륨산화물(Barium Oxide)을 넣고 유리판을 붙였다.A blue fluorescent organic light-emitting device was prepared in the same manner as in Example 1 except that ITO (180 nm) / 2-TNATA (60 nm) / NPB (20 nm) / αβ-ADN: 9,9-diethyl- -9H-fluorene was deposited in the order of 10% (30 nm) / Bphen (40 nm) / Liq (2 nm) / Al (100 nm). Before deposition of the organic material, the ITO electrode was subjected to oxygen plasma treatment at 125 W for 2 minutes at 2 × 10 -2 Torr. Organic matters were deposited at a vacuum of 9 × 10 -7 Torr. The blue fluorescent dopant was co-deposited with 0.02 Å / sec on Liq and 0.18 Å / sec on αβ-ADN. / sec. &lt; / RTI &gt; The blue fluorescent dopant used in the experiment was 9,9-diethyl-2,7-bis ((E) -4-tritylstyryl) -9H-fluorene and the concentration of the dopant was fixed at 10%. After fabricating the device, it was sealed in a glove box filled with nitrogen gas to prevent air and moisture contact of the device. Barium oxide (Barium Oxide), which is a hygroscopic agent capable of removing moisture and so on, was put into a glass plate after 3M's adhesive tape was formed.

Figure 112014105058503-pat00082

Figure 112014105058503-pat00082

시험예Test Example 1 :  One : ITOITO / 2- / 2- TNATATNATA /  / NPBNPB / αβ- / αβ- ADNADN , , 실시예Example 3(화합물 4-3) /  3 (Compound 4-3) / BphenBphen /   / LiqLiq /  / AlAl

상기 비교시험예에서 이용한 청색형광 도판트 물질 대신 상기 실시예 3에서 제조한 화합물을 발광층으로 이용한 것을 제외하고는 상기 비교시험예와 동일한 방법으로 소자를 제작하였다.A device was prepared in the same manner as in the comparative test except that the compound prepared in Example 3 was used as a light emitting layer instead of the blue fluorescent dopant used in the above Comparative Test Example.

시험예Test Example 2 :  2 : ITOITO / 2- / 2- TNATATNATA /  / NPBNPB / αβ- / αβ- ADNADN , , 실시예Example 18(화합물 4-18) / Bphen /  18 (Compound 4-18) / Bphen / LiqLiq /  / AlAl

상기 비교시험예에서 이용한 청색형광 도판트 물질 대신 상기 실시예 18에서 제조한 화합물을 발광층으로 이용한 것을 제외하고는 상기 비교시험예와 동일한 방법으로 소자를 제작하였다.A device was fabricated in the same manner as in the comparative test except that the compound prepared in Example 18 was used as a light emitting layer in place of the blue fluorescent dopant used in the above Comparative Test Example.

상기 비교시험예 및 시험예 1 내지 2에서 제조된 유기 발광 소자에 대한 전기적 발광특성을 표 3에 나타내었다.
Table 3 shows the electroluminescence characteristics of the organic luminescent devices prepared in the Comparative Test Examples and Test Examples 1 and 2.

구분division 색좌표(x,y)The color coordinates (x, y) EL peak (nm)EL peak (nm) 발광효율 (cd/A)
@20mA/㎠
The luminous efficiency (cd / A)
@ 20 mA / cm 2
외부양자효율(%)
@20mA/㎠
External quantum efficiency (%)
@ 20 mA / cm 2
비교시험예 Comparative test example (0.17, 0.19)(0.17, 0.19) 456456 1.891.89 1.201.20 시험예1Test Example 1 (0.16, 0.19)(0.16, 0.19) 476476 3.233.23 2.312.31 시험예2Test Example 2 (0.16, 0.22)(0.16, 0.22) 481481 2.852.85 1.791.79

상기 표 3 및 하기 도 2로 확인할 수 있는 바와 같이 본 발명의 화합물들을 발광층으로 사용하여 제작한 소자는 청색 파장 영역에서 발광하며, 시험예 1~2의 소자가 비교시험예의 소자에 비해 발광 효율 및 외부양자효율 특성이 모두 향상됨을 확인할 수 있다. 이러한 발광 효율 및 외부양자효율 특성의 향상은 낮은 구동전압과 발광 효율이 개선된 유기 전계발광 소자를 제공할 수 있다. As can be seen from Table 3 and FIG. 2, the device fabricated using the compounds of the present invention as a light emitting layer emits light in the blue wavelength region, and the devices of Test Examples 1 and 2 have higher luminous efficiency and And the external quantum efficiency characteristics are all improved. The improvement of the luminous efficiency and the external quantum efficiency characteristic can provide an organic electroluminescent device with improved driving voltage and luminous efficiency.

Claims (9)

하기 화학식 1로 표시되는 이미다졸 유도체.
[화학식 1]
Figure 112016059557428-pat00083

[상기 화학식 1에서,
p는 1 또는 2이고, L은 단일결합이고, q는 0 또는 1이며,
A는 q가 0일 경우,
Figure 112016059557428-pat00121
또는
Figure 112016059557428-pat00122
이고,
q가 1일 경우, 하기 화학식 3으로부터 선택되는 어느 하나임.]
[화학식 3]
Figure 112016059557428-pat00123
Figure 112016059557428-pat00124
Figure 112016059557428-pat00125
Figure 112016059557428-pat00126

Figure 112016059557428-pat00127
Figure 112016059557428-pat00128
Figure 112016059557428-pat00129
Figure 112016059557428-pat00130

Figure 112016059557428-pat00131
Figure 112016059557428-pat00132
Figure 112016059557428-pat00133
Figure 112016059557428-pat00134

Figure 112016059557428-pat00135
An imidazole derivative represented by the following formula (1).
[Chemical Formula 1]
Figure 112016059557428-pat00083

[In the above formula (1)
p is 1 or 2, L is a single bond, q is 0 or 1,
A is, when q is 0,
Figure 112016059557428-pat00121
or
Figure 112016059557428-pat00122
ego,
and when q is 1, it is selected from the following formula (3).
(3)
Figure 112016059557428-pat00123
Figure 112016059557428-pat00124
Figure 112016059557428-pat00125
Figure 112016059557428-pat00126

Figure 112016059557428-pat00127
Figure 112016059557428-pat00128
Figure 112016059557428-pat00129
Figure 112016059557428-pat00130

Figure 112016059557428-pat00131
Figure 112016059557428-pat00132
Figure 112016059557428-pat00133
Figure 112016059557428-pat00134

Figure 112016059557428-pat00135
삭제delete 삭제delete 제 1항에 있어서,
상기 화학식 1로 표시되는 화합물은 하기 화학식 4에서 선택되는 것을 특징으로 하는 이미다졸 유도체.
[화학식 4]
Figure 112016059557428-pat00102

Figure 112016059557428-pat00103

Figure 112016059557428-pat00104
The method according to claim 1,
The imidazole derivative according to claim 1, wherein the compound represented by the formula (1) is selected from the following formula (4).
[Chemical Formula 4]
Figure 112016059557428-pat00102

Figure 112016059557428-pat00103

Figure 112016059557428-pat00104
제 1항 또는 제 4항의 이미다졸 유도체를 포함하는 유기 전계발광 소자.An organic electroluminescent device comprising the imidazole derivative of claim 1 or 4. 제 5항에 있어서,
상기 이미다졸 유도체가 발광층의 재료로 사용되는 것을 특징으로 하는 유기 전계발광 소자.
6. The method of claim 5,
Wherein the imidazole derivative is used as a material of the light emitting layer.
제1 전극, 제2 전극, 및 상기 전극들 사이에 배치된 1층 이상의 유기막을 포함하되,
상기 유기막은 제 1항 또는 제 4항의 이미다졸 유도체를 포함하는 유기 전계발광 소자.
A first electrode, a second electrode, and at least one organic film disposed between the electrodes,
Wherein the organic film comprises the imidazole derivative of claim 1 or claim 4.
제 7항에 있어서,
상기 유기막은 정공주입층, 정공수송층, 정공주입 기능과 정공수송 기능을 동시에 갖는 기능층, 버퍼층, 전자저지층, 발광층, 정공저지층, 전자수송층, 전자주입층, 및 전자수송 기능과 전자주입 기능을 동시에 갖는 기능층으로 이루어진 군 중에서 선택되는 1층 이상을 포함하는 유기 전계발광 소자.
8. The method of claim 7,
The organic layer includes a hole injecting layer, a hole transporting layer, a functional layer having both a hole injecting function and a hole transporting function, a buffer layer, an electron blocking layer, a light emitting layer, a hole blocking layer, an electron transporting layer, And at least one functional layer having at least one functional group at the same time.
제 7항에 있어서,
상기 이미다졸 유도체가 상기 유기막을 구성하는 전자저지층, 전자수송층, 전자주입층, 전자수송 기능과 전자주입 기능을 동시에 갖는 기능층 및 발광층으로 이루어진 군 중에서의 선택된 어느 1층에 포함되는 것을 특징으로 하는 유기 전계발광 소자.
8. The method of claim 7,
The imidazole derivative is contained in any one selected from the group consisting of an electron blocking layer, an electron transport layer, an electron injection layer, a functional layer having both an electron transport function and an electron injection function, and a light emitting layer constituting the organic film The organic electroluminescent device comprising:
KR1020140150036A 2014-10-31 2014-10-31 Imidazole derivative and organic electroluminescent device including the same KR101670904B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140150036A KR101670904B1 (en) 2014-10-31 2014-10-31 Imidazole derivative and organic electroluminescent device including the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140150036A KR101670904B1 (en) 2014-10-31 2014-10-31 Imidazole derivative and organic electroluminescent device including the same

Publications (2)

Publication Number Publication Date
KR20160050891A KR20160050891A (en) 2016-05-11
KR101670904B1 true KR101670904B1 (en) 2016-10-31

Family

ID=56025760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140150036A KR101670904B1 (en) 2014-10-31 2014-10-31 Imidazole derivative and organic electroluminescent device including the same

Country Status (1)

Country Link
KR (1) KR101670904B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011360B (en) * 2017-03-14 2020-08-11 上海大学 Heterocyclic-carboline derivative and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104030988A (en) 2014-06-25 2014-09-10 上海道亦化工科技有限公司 Benzimidazole-based electron transport compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104030988A (en) 2014-06-25 2014-09-10 上海道亦化工科技有限公司 Benzimidazole-based electron transport compound

Also Published As

Publication number Publication date
KR20160050891A (en) 2016-05-11

Similar Documents

Publication Publication Date Title
KR101806464B1 (en) Pyrimidine derivative substitued with pyridyl group, and organic electroluminescent device including the same
KR101427605B1 (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR101694492B1 (en) Amine compound and organic electroluminescent device using the same
KR101293320B1 (en) Aromatic amine derivative and organic electroluminescent element using same
KR101674134B1 (en) triazine derivatives and organic electroluminescent device including the same
TW201300499A (en) Novel organic electroluminescent compound and organic electroluminescent device including the same
TW201305106A (en) Compound for organic electronic element, organic electronic element using the same, and electronic device thereof
KR20140099082A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
US20100244012A1 (en) Naphthyl-substituted anthracene derivatives and their use in organic light-emitting diodes
KR101165698B1 (en) Organic electronic element comprising a new compound, and a new compound and a composition for organic electronic element
KR101813692B1 (en) pyrimidine derivatives substituted with heteroaryl-substituted phenyl group, and organic electroluminescent device including the same
KR20170058619A (en) Pyrimidine derivative substituted with phenyl group, and organic electroluminescent device including the same
KR101415734B1 (en) Hole transporting material using new arylamine and organic electroluminescent device comprising the same
US10224489B2 (en) Compound and organic electronic device using the same
KR101635154B1 (en) pyridyl substituted triazine derivatives and organic electroluminescent device including the same
KR101098612B1 (en) BENZO[a]FLUORANTHENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME
KR101950255B1 (en) Compound for organic electronic element, organic electronic element using the same, and a electronic device thereof
KR101661591B1 (en) triazolyl substituted pyrene derivatives and organic electroluminescent device including the same
KR101648009B1 (en) Azafluorene substituted Triazine derivative and organic electroluminescent device including the same
KR101714509B1 (en) Dibenzo-benzimidazol derivatives and organic electroluminescent device including the same
KR101508145B1 (en) Organic electroluminescent compound, producing method of the same and organic electroluminescent device including the same
KR101528767B1 (en) Antracene derivative and organic electroluminescent device including the same
KR20170058623A (en) Pyrimidine derivatives substituted with heteroaryl substituted-pyridyl or -phenyl, and organic electroluminescent device including the same
JP2005272805A (en) Organic material and organic electroluminescent element
KR101670904B1 (en) Imidazole derivative and organic electroluminescent device including the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20190918

Year of fee payment: 4